Literature DB >> 27466921

The FDA Revises Restrictions on Metformin Use in Kidney Impairment.

Diane S Aschenbrenner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27466921     DOI： 10.1097/01.NAJ.0000490173.76651.27

Source DB:  PubMed          Journal:  Am J Nurs        ISSN： 0002-936X            Impact factor:   2.220


× No keyword cloud information.
  3 in total

1.  Metformin ameliorates the severity of experimental Alport syndrome.

Authors:  Kohei Omachi; Shota Kaseda; Tsubasa Yokota; Misato Kamura; Keisuke Teramoto; Jun Kuwazuru; Haruka Kojima; Hirofumi Nohara; Kosuke Koyama; Sumio Ohtsuki; Shogo Misumi; Toru Takeo; Naomi Nakagata; Jian-Dong Li; Tsuyoshi Shuto; Mary Ann Suico; Jeffrey H Miner; Hirofumi Kai
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

2.  Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study.

Authors:  Stephen Wood; Dianna J Magliano; J Simon Bell; Jonathan E Shaw; Jenni Ilomäki
Journal:  Front Pharmacol       Date:  2021-12-14       Impact factor: 5.810

3.  Metabolic profiling of metformin treatment for low-level Pb-induced nephrotoxicity in rat urine.

Authors:  Yu-Shen Huang; Shwu-Huey Wang; Shih-Ming Chen; Jen-Ai Lee
Journal:  Sci Rep       Date:  2018-10-01       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.